Status:
COMPLETED
Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
DiaSorin ; Saluggia, Italia
Conditions:
Hypophosphatemia Without Immediate Anteriority
Unexplained Hypophosphatemia
Eligibility:
All Genders
18+ years
Brief Summary
The discovery of FGF23, the missing link in the long researched and finally found phosphate metabolism, marked a turning point in the understanding and physiopathology of specific hypophosphatemia. By...
Detailed Description
To date, even if the incidence of FGF23-secreting tumours seems rare, no precise bibliographical data is available in the scientific literature. Future studies will have to address this issue in order...
Eligibility Criteria
Inclusion
- Major patient, male or female
- Taken care of at the Clermont-Ferrand University Hospital or the Jean Perrin Centre
- In a context of hypophosphatemia (\< 0.80 mmol/L), without immediate anteriority and not occurring during hospitalisation
- In capacity to express informed consent to participate in research
- Affiliated to a social security system
Exclusion
- Previously diagnosed hypophosphatemia
- Hypophosphatemia during hospitalisation
- Haemodialysis patient
- Refusal to participate
Key Trial Info
Start Date :
October 5 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 25 2022
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT04846647
Start Date
October 5 2021
End Date
April 25 2022
Last Update
May 11 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Clermont Ferrand
Clermont-Ferrand, France, 63003
2
Centre Jean Perrin
Clermont-Ferrand, France